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ABSTRACT
MeCP2 is a methyl-CpG-binding protein that is a
main component of brain chromatin in vertebrates.
In vitro studies have determined that in addition to
its specific methyl-CpG-binding domain (MBD)
MeCP2 also has several chromatin association
domains. However, the specific interactions of
MeCP2 with methylated or non-methylated chroma-
tin regions and the structural characteristics of the
resulting DNA associations in vivo remain poorly
understood. We analysed the role of the MBD in
MeCP2–chromatin associations in vivo using an
MeCP2 mutant Rett syndrome mouse model
(Mecp2tm1.1Jae) in which exon 3 deletion results in
an N-terminal truncation of the protein, including
most of the MBD. Our results show that in mutant
mice, the truncated form of MeCP2 ("MeCP2) is ex-
pressed in different regions of the brain and liver,
albeit at 50% of its wild-type (wt) counterpart. In
contrast to the punctate nuclear distribution char-
acteristic of wt MeCP2, "MeCP2 exhibits both
diffuse nuclear localization and a substantial reten-
tion in the cytoplasm, suggesting a dysfunction of
nuclear transport. In mutant brain tissue, neuronal
nuclei are smaller, and "MeCP2 chromatin is
digested faster by nucleases, producing a charac-
teristic nuclease-resistant dinucleosome. Although
a fraction of "MeCP2 is found associated with nu-
cleosomes, its interaction with chromatin is transi-
ent and weak. Thus, our results unequivocally
demonstrate that in vivo the MBD of MeCP2
together with its adjacent region in the N-terminal
domain are critical for the proper interaction of the
protein with chromatin, which cannot be replaced
by any other of its protein domains.
INTRODUCTION
Methyl-CpG-binding protein 2 (MeCP2) is a basic
chromosomal protein that binds to symmetrical
methylated 50CpG dinucleotide sequences (1). Although
the protein consists of several well-defined structural
domains (2) (Figure 1A), it is an excellent example of an
intrinsically disordered protein (5) because of a very low
content of secondary structure organization (40%) (5,6).
Intrinsically disordered proteins contain low levels of sec-
ondary structure that can increase on interaction with
other binding partners (7). In addition to DNA, MeCP2
has numerous protein interaction partners (8) and has
been shown to interact with RNA (9). It should thus not
come as a surprise that mutations throughout the whole
protein have potentially deleterious consequences.
The protein is encoded by a single-copy gene located in
the X-chromosome and contains 4 exons. Alternative
splicing of exon 2 results in two isoforms, E1 and E2,
that differ only in the first 24 N-terminal amino acids
(10). For historical reasons, many of the structural
features of MeCP2 are referred to the shorter E2
isoform, which was identified first in rat (11). Although
discovered later, the longer E1 isoform is by far the most
abundant (10-fold higher in brain tissue) (10,12,13) and
will be used as a reference throughout this article
(Figure 1A).
The structural organization resulting from interactions
of MeCP2 with DNA and chromatin templates has been
studied extensively in vitro (14–20) and to a lesser extent
in situ (20–22). However, interpreting conclusions from
*To whom correspondence should be addressed. Tel: +1 250 721 8863; Fax: +1 250 721 8855; Email: jausio@uvic.ca
4888–4900 Nucleic Acids Research, 2013, Vol. 41, No. 9 Published online 4 April 2013
doi:10.1093/nar/gkt213
 The Author(s) 2013. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Downloaded from https://academic.oup.com/nar/article-abstract/41/9/4888/2409621
by guest
on 24 July 2018
in vitro studies is complicated in part by the difficulty in
reproducing the conditions occurring within the native
nuclear environment. In addition to the difficulty in
replicating the exact ionic composition and concentrations
in the nucleus, the methyl binding preference of MeCP2 by
DNA and nucleosome templates can only be mimicked in
the presence of competitor DNA (20,23). MeCP2 is a
highly basic protein that will bind indiscriminately to
DNA under conditions of sufficiently low ionic strength.
As a result, the preference of MeCP2 for methylated DNA
templates, as assessed from the in vitro work, has remained
controversial [reviewed in (2)]. Although the interactions
of MeCP2 with methylated and non-methylated regions of
DNA in vivo remain an issue for discussion [reviewed in
(8)], high-throughput DNA sequencing has demonstrated
a strong correlation between DNA methylation and the
MeCP2 distribution (24,25).
MeCP2 is an X-linked gene, and mutations are
associated with >85% of the cases of Rett syndrome
(RTT) (26). RTT is a neurodevelopmental disease that
affects mainly females, as males hemizygous for the
mutation are severely affected (27). As a result of this as-
sociation, a large amount of the initial research on this
protein has focused on this disease. An important part
of this effort has been directed towards the development
of several mouse models that recapitulate phenotypic
features of the human disorder (8). Two well-studied
lines are Mecp2tm1.1Bird (28) and Mecp2tm1.1Jae (29), both
originally described as protein-null mutations. In the
Mecp2tm1.1Bird line, exons 3 and 4 were deleted, resulting
in a complete knockout of protein expression.
Mecp2tm1.1Jae mice contain an in-frame deletion of exon
3. The status of Mecp2tm1.1Jae mice as protein-null has
remained contentious, although subsequent characteriza-
tions have confirmed the presence of stable mRNA (30)
and suggested that a truncated protein may be present
(31). Direct phenotypic comparisons of the two lines has
supported the presence of a partially functional protein in
Mecp2tm1.1Jae mice, which have shown a different and
often milder phenotype for many parameters, including
brain weight, brain region volumes, dendritic spine
morphology and cerebellar gene expression profiles
(30,32,33).
As a result of the exon 3 deletion in the Mecp2tm1.1Jae
model (29), the truncated version of MeCP2 lacks 116
N-terminal amino acids, including the 48 N-terminal
amino acids of the methyl-CpG-binding domain (MBD),
as well as the first ‘enriched in proline, glutamic, serine
and threonine’ (PEST) sequence. However, within exon
4, it retains the complete transcriptional repressor
domain, the nuclear localization signal (NLS) (3) and
the PEST 2 sequence (4) (Figure 1A). Consequently, this
mouse model provides a valuable tool in trying to address
the question about the effect of a disrupted MBD on
MeCP2–chromatin interactions in vivo. Furthermore,
several MeCP2 mutations in patients suffering from
RTT occur within the MBD, including R106W,
R1333C, P152R, F155S and T158M. Of those, R106W
takes place within the region of MBD truncated in the
Mecp2tm1.1Jae mouse model.
Our results show that the N-terminal truncated
MeCP2 is still capable of binding to DNA and chroma-
tin, but that the binding specificity is significantly
impaired, suggesting that interactions with methylated
DNA are necessary for binding specificity. The trafficking
of the protein from the cytoplasm to the nucleus is also
altered, despite the retained NLS. Our results demonstrate
that the RTT-like phenotypic characteristics of the
Mecp2tm1.1Jae mutant mouse model are a consequence of
the truncated protein’s inability to properly recognize
features of methylated chromatin, impaired nuclear
import and accelerated protein turnover.
MATERIALS AND METHODS
Animal breeding
Mecp2 mutant mice (Mecp2tm1.1Jae/Mmcd) (MMRRC,
UC Davis) (29) and yellow fluorescent protein (YFP)-H
transgenic mice [B6.Cg-Tg(Thy1-YFPH)2Jrs/J, Jackson
Laboratory Sacramento, CA, USA) (34) were bred and
genotyped as described elsewhere (35).
Chromatin preparation and fractionation
Chromatin purification and fractionation was carried out
as described elsewhere (22).
Time course micrococcal nuclease digestions of mouse
liver and brain nuclei were carried out in 50mM NaCl,
10mM piperazine-N,N0-bis(2-ethanesulfonic acid)
(PIPES), pH 6.8, 5mM MgCl2, 1mM CaCl2 buffer with
2U of micrococcal nuclease per milligram of DNA for 8,
16, 24 and 32min.
Sucrose gradient fractionation
Chromatin fractions S1 and SE were prepared as
described previously (22) and were run on 5–20%
sucrose gradients in 25mM NaCl, 10mM Tris, pH 7.5,
and 5mM EDTA buffer for 21 h at 96 000g and 4C and
collected thereafter in 0.5-ml aliquots.
Cytoplasmic and nuclear fractionation
Briefly, wild-type (wt) and mutant brain and liver tissues
were homogenized in 1 phosphate-buffered saline (PBS)
(137mM NaCl, 2.7mM KCl, 4.3mM Na2HPO4 and
1.47mM KH2PO4) and centrifuged at 4500g for 10 min
at 4C. The pellet was added to 1 PBS, and the sample
was split in two aliquots. One half was kept (starting
MeCP2), while the other half was centrifuged at 4500g
for 10 min. The cellular pellet was homogenized in 0.25
M sucrose, 0.5% NP 40 buffer 1, incubated for 10 min on
ice and centrifuged at 4500g to produce a supernatant
cytoplasmic MeCP2 fraction and a pellet nuclear
MeCP2 fraction. The samples were mixed with 2 SDS
sample loading buffer and analysed by western blot.
Gel electrophoresis
SDS–(15%) PAGE (36), acetic acid–urea (AU)–PAGE
(37), acetic acid–urea–Triton X-100 (AUT)–(10%)
PAGE (38), native-(4%) PAGE (39) and 1% agarose
gels were performed as described earlier (40,41).
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Histological preparation
Animals were anaesthetized using urethane (2 g/kg i.p.)
(Sigma-Aldrich, St. Louis, MO, USA) and transcardially
perfused with 10ml of 0.1 M PBS (pH 7.4), 10ml of 4%
formaldehyde at room temperature in 0.1 M phosphate
buffer (PFA), pH 6.5, followed by 10ml of PFA, pH 11,
with a 2-h post-fix in PFA, pH 11. Brain tissue was dis-
sected out and fixed in 4% PFA at 4C overnight,
washed three times in PBS and sunk in 30% sucrose–
PBS. Agar-embedded 200-mm coronal sections were cut
on a Pelco Vibratome 1000 and coverslipped with
Shandon Immunomount (Thermo Scientific Rockford,
IL, USA). Animals used for MeCP2 immunofluorescence
were processed in the same manner except for fixation
conditions: 10ml of PFA, pH 6.5, followed by 10ml of
PFA, pH 11, with a 2-h post-fix in PFA, pH 11.
Cryopreserved brains were frozen on dry ice, and 50-
mm coronal sections were cut on a Leica CM1850 UV
cryostat.
Western blotting
Whole brain homogenates from 8-week-old wt and
MeCP2 mutant littermates were prepared in 4 volumes
of solution A [0.32 M sucrose, 1mM MgCl2, 0.5% (w/v)
NP-40], incubated for 15 min on ice and centrifuged for
10min at 5000g at 4C. Pellets were resuspended in
solution A and recentrifuged as described above. The
pellets were then taken through two rounds of resuspen-
sion and centrifugation in 4 volumes of solution B [50 mM
NaCl, 5mM MgCl2, 1mm CaCl2, 10mM PIPES (pH 6.8)]
at 8000g for 10min at 4C. The final pellets were resus-
pended in equal volumes of solution B and 2 SDS–
PAGE buffer to a DNA concentration of 2mg/ml,
boiled for 3min at 100C, loaded on a 15% SDS–PAGE
gel and blotted onto a polyvinylidene difluoride (PVDF)
membrane. All samples contained Complete Protease
Cocktail Inhibitor (Roche Molecular Biochemicals,
Laval, Quebec, Canada) at a 1:100 dilution. The primary
antibodies used were a polyclonal rabbit a-MeCP2
(M9317) targeting C-terminal amino acids 465–478
(Sigma-Aldrich St. Louis, MO, USA) at 1:2000 dilution,
and monoclonal mouse a-MeCP2 against N-terminal
amino acids 81–170 (Clone 4B6) (Sigma-Aldrich St.
Louis, MO) at 1:5000 dilution. Secondary antibodies
used were horseradish peroxidase-conjugated anti-rabbit
(Jackson ImmunoResearch Inc., West Grove, PA, USA)
at 1:10 000 dilution and anti-mouse (Rockland
Immunochemicals, Gilbertsville, PA, USA) at 1:3000
dilution. Visualization was performed using enhanced
chemiluminescence (ECL) (PerkinElmer, Santa Clara,
CA, USA).
For quantitative western analysis, the proteins of the
SDS–PAGE were blotted onto a 0.2-mm nitrocellulose
membrane, using 25mM Tris base with 192mM glycine
as transfer buffer. The antibodies used were SIGMA M
9317 a-MeCP2 at a 1:2000 dilution, mouse polyclonal
anti-histone H1 [0.T.60] Cat no. ab4269 (Abcam,
Cambridge, MA, USA) at a 1:500 dilution and an anti-
histone H4 (prepared in-house) at a 1:10 000 dilution. The
secondary antibodies used were as follows: anti-rabbit
IRDye 800-conjugated antibody, cat no. 611-132-122
(Rockland, Gilbertsville, PA, USA) at a 1:5000 dilution
and goat anti-mouse IRDye 680, Cat no.926-32220 (LI-
COR Biosciences, Lincoln, NE, USA) at a 1:10 000 dilu-
tion. Membrane was incubated with secondary antibodies
in dark conditions for 1 h and visualized using Odyssey
Licor Developer v.2.1. Band intensity was quantified using
Licor software.
Immunohistochemistry
Tissue sections were permeabilized in 1% PBST (PBS,
pH 7.4, with 1% Triton X-100) and blocked overnight
in 5% goat serum. All antibody incubations were done
for 24 h at room temperature in 0.1% PBST. A chicken
a-MeCP2 antibody targeting C-terminal amino acids
466–484 (gift from Janine LaSalle, UC Davis) and
mouse a-MeCP2 4B6 were used as primary antibodies
at a 1:5000 dilution. Alexa 555-conjugated goat anti-
chicken and Alexa 647-conjugated goat anti-mouse
(Invitrogen, Carlsbad, CA, USA) were used as second-
ary antibodies (1:500). YO-PRO-1 (1:10 000)
(Invitrogen, Carlsbad, CA, USA) was used as a
nuclear counter-stain. Sections were mounted on
Vectashield Hard Set medium (Vector Laboratories,
Burlingame, CA, USA), coverslipped and allowed to
set for 24 h before imaging.
Plasmid constructs
Wild-type and mutant MeCP2 cDNAs (20) were used in
conjunction with the following primers: 50-GCGCGAAT
TCAGTAGCTGGGATGTTAGGGCT-30/50-GCGCGG
ATCCTCAGCT AACTCTCTCGGTCAC-30 and cloned
into the pEGFP-C1 plasmid (Clontech, Mountain View,
CA, USA) to allow expression of C-terminal EGFP-
tagged wt and mutant MeCP2 under the control of the
hCMV IE promoter.
Cell culture and plasmid transfection
The Neuro-2A (N2A) mouse neuroblastoma cell line
(ATCC) was used for live-cell plasmid transfection experi-
ments. N2A cells were cultured at 37C and 5% CO2 in
equal parts high-glucose Dulbecco’s modified Eagle’s
medium and minimal essential medium (MEM)+
glutamax (GIBCO/Invitrogen, Carlsbad, CA, USA), sup-
plemented with 10% fetal bovine serum (Invitrogen,
Carlsbad, CA, USA), 2mM L-glutamine (Sigma-Aldrich,
St. Louis, MO, USA), 100U/ml of penicillin (Sigma-
Aldrich, St. Louis, MO, USA) and 100 mg/ml of strepto-
mycin (Sigma-Aldrich, St. Louis, MO, USA). The day
before plasmid transfections, 1.0 106 N2A cells were
seeded into 35-mm glass bottom culture dishes (No. 1.5
coverglass; MatTek). Coverslips were coated with 1%
gelatin for 2.5 h before seeding. Cells were transfected
with 2 mg of plasmid DNA/plate using Lipofectamine
2000 (Invitrogen, Carlsbad, CA, USA) following manu-
facturer’s instructions, incubated for 18 h in serum- and
antibiotic-free culture medium and then cultured for 48 h
in complete medium. Hoechst 33342 TriHCl (Molecular
Probes/Invitrogen, Carlsbad, CA, USA) was added to
culture media 30min before imaging. Immediately prior
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to imaging, cells were washed twice with pre-warmed
HEPES-buffered extracellular solution, pH 7.4 (150mM
NaCl, 4mM KCl, 2mM MgCl2, 2mM CaCl2, 10mM
HEPES, 10mM glucose and 2mM ascorbic acid). Cells
were maintained in extracellular solution at 37C during
imaging using a TC-344B Dual Automatic Temperature
Controller (Warner Instrument Corp., Hamden, CT,
USA).
Imaging and image analysis
For MeCP2 immunofluorescence, 1024 1024 pixel 3D
confocal fluorescence image stacks were obtained using
an Olympus Fluoview FV1000 with Fluoview software
(v. 1.7 c) with 488-, 543- and 635-nm lasers, an Olympus
Plan SApo NA 0.95 40 oil objective with 10 2-mm
z-steps and pinhole size set automatically (85–120 mm).
Multi-channel imaging was done sequentially. All images
were averaged twice with scan speeds of 1.68–3.94 ms/pixel
(Olympus, Center Valley, PA, USA).
For Neuro-2A live-cell imaging, monochromatic
2560 1920 pixel wide-field fluorescence images were
obtained using a Nikon 100/1.49 NA Apo TIRF ob-
jective (Nikon, Melville, NY, USA), 1.5 zoom, with a
Nikon DS-U1 camera and ACT-2U software. Images
were converted to 8-bit .tif files, processed and analysed
using ImageJ software (NIH). Green fluorescent protein
(GFP)/Hoechst image pairs were converted to stacks,
and noise pixels were smoothed using a 2-pixel median
filter. The means and standard deviations of nuclear
greyscale intensity values were obtained over the same
outlined area for both channels. Nuclei from 27 wt and
22 mutant cells were outlined based on the Hoechst-
staining pattern. Coefficients of variation were generated
for MeCP2-GFP and Hoechst staining by dividing the
greyscale standard deviation by the mean intensity for
each cell. A ratio of the coefficients of variations
(MeCP2-GFP/Hoechst) was generated for each cell.
Genotypes were compared using the Mann–Whitney U-
test. Images used for the pixel intensity line plots through
the soma and nucleus were converted to 32-bit .tif files,
and greyscale values were squared to enhance contrast.
Images were adjusted for brightness and contrast and
tiled using Adobe Photoshop CS4.
Fluorescence recovery after photobleaching
WtMeCP2-GFP and MeCP2-GFP plasmids with
C-terminal GFP were constructed (42) and analysed by
fluorescence recovery after photobleaching (FRAP) as
described elsewhere (43).
Preparation of tissue samples for real-time quantitative
polymerase chain reaction
Brain tissue samples from 8-week-old animals (wt n=5,
MeCP2 n=4) were rapidly dissected, flash-frozen in
isopentane chilled to 20C and stored at 80C.
Tissues were transferred to chilled RNAlater ice (Life
Technologies) at 20C for at least 16 h before RNA ex-
traction. Approximately 100–150mg of brain tissue was
homogenized in 1 ml of TRIzol (Invitrogen, Carlsbad,
CA, USA) using 3-mm stainless steel beads and 1.5 ml
Safe-Lock Eppendorf microcentrifuge tubes in a Retsch
MM301 Mixer Mill (Fisher Scientific Ltd., Ottawa,
Ontario, Canada) at 25 Hz for 9 min. RNA was isolated
according to the manufacturer’s instructions. Extracted
RNA was resuspended in 30 ml of RNase-free dH2O and
stored at 80C. QuantiTect Reverse Transcription
cDNA Synthesis Kit (Qiagen, Germantown, MD, USA)
was used to synthesize cDNA from 1 mg of total RNA as
described by the manufacturer (Qiagen, Germantown,
MD, USA). The cDNA reactions were diluted 20-fold
for use in PCR amplification. Total RNA and cDNA
quality was confirmed by 1.5% agarose gel
electrophoresis.
The RT–PCR primer sequences used were: MECP2
primers: forward 50-CCCAGGTTTTGTGCTTTGTT
and reverse 50-GGGAGTGCTCTTGTCTCCTG (104-bp
amplicon); rp L8 primers: forward 50-AAAGGCATCGT
AAAGGACAT and reverse 50-ACCAGCCACAACACC
AAC (376-bp amplicon). rp L8 was used to normalize the
target gene (MECP2) and to account for any reference
gene expression variations that may be present between
different samples (44). The suitability of the target and
reference gene primers for RT–PCR was assessed by
serial dilution validation assay. The slope of the Ct
(MeCP2 gene primer minus rpL8 normalizer gene
primer), for the MeCP2 primer, versus log cDNA concen-
tration dilution was <0.1, and efficiency of the primer set
was >99%.
RT–PCR was conducted using the First Strand
Universal SYBR Green Master Mix with Rox (Roche
Molecular Biochemicals, Laval, Quebec, Canada) with
an Agilent Technologies Stratagene Mx3005P
thermocycler. Transcript levels were analysed using
MxPro-Mx3005P v4.10 Build 389, Schema 85 software
(Stratagene, La Jolla, CA, USA). Cycling parameters
were Segment 1 (1 cycle): 9min. denaturation at
94C; Segment 2 (40 cycles): 15 s denaturation at
95C, 30 s annealing at 62C, 45 s extension at 72C;
Segment 3 (1 cycle—for dissociation profile): 1min at
95C, 30 s at 55C, 30 s at 95C. Each cDNA 1/20
dilution was run in quadruplicates as were cDNA
template-free controls to test for any DNA contamin-
ation. Quadruplicate Ct values were averaged for
mutant and wt samples, and average Ct values were
normalized to the rp L8 control using the comparative
Ct method (Ct ). Data analysis was done using
comparative Ct (2-Ct) method (45) with one wt
sample as the comparator for the mutant samples to
determine the relative fold changes in Mecp2 expression
levels (45–47). The specificity of the amplification reac-
tions was determined by sharpness of dissociation
curves and matching of melting temperature (Tm)
between samples.
Statistical analyses were conducted using Prism 5
v.5.0.b (Graphpad Software). All data were analysed
using the two-tailed unpaired student’s t-test unless
otherwise indicated. Results were considered significant
at P< 0.05 and reported as the mean±SEM. Data set
distributions were tested for normality using the
D’Agostino and Pearson omnibus normality test.
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RESULTS
MeCP2 protein missing the sequence corresponding to
exon 3 of Mecp2tm1.1Jae mutant mice is expressed at
reduced levels in different regions of the brain and liver
The expression of MeCP2 in the Mecp2tm1.1Jae mouse
model of RTT has been controversial. Although the first
report of the mutant phenotype showed expression of a
faster electrophoretic band by western blot analysis (29), a
later report found stable mRNA but was unable to detect
the protein by western blot (30).
We therefore decided to revisit this issue. Nuclear frac-
tions from 8- to 11-week-old Mecp2tm1.1Jae mutant and wt
mice were probed by western blot using two antibodies, a
mouse a-MeCP2 targeting the N-terminus and a rabbit
a-MeCP2 targeting the C-terminus (Figure 1B). The first
45 of 89 amino acids of the N-terminal antibody epitope
are deleted in the mutant protein. Consistent with the pre-
dicted labelling pattern, the C-terminal a-MeCP2
generated both a high MW band in the wt mouse and a
fainter, faster band (corresponding to a lower molecular
mass) in the mutant, whereas the N-terminal a-MeCP2
only labelled an identical high-molecular mass band in
the wt mice. These results are in agreement with the
results from the group that created the mouse model (29).
Western blot quantification of the amount of protein
expressed in whole brain homogenates carried out as
described previously (22) and using IRDye green fluores-
cence indicated that 35±3% of the truncated protein is
present in the Mecp2tm1.1Jae mice, a result that closely re-
sembles the western shown in Figure 1E of Chen et al.
(29). As seen in Figure 1C, the RT–PCR graph shows a
trend towards a decrease in the relative abundance of
MeCP2 mRNA in agreement with Chen et al. (29),
who reported a reduced MeCP2 transcript in mutant
brain using northern-blot analysis. However, statistical
analysis of the data in Figure 1C (see ‘Materials and
Methods’ section) revealed that, despite the trend, there
was no significant difference (t7=0.9716, P =0.3636)
between wt MeCP2 and MeCP2.












































Figure 1. Expression of MeCP2 in Mecp2tm1.1Jae mutant mice. (A) Schematic representation of mouse MeCP2 E1. The N-terminal domain (NTD),
MBD, the ID, the C-terminal domains (2), NLS (32) and the two PEST sequences (33) are indicated. (B) SDS–PAGE and western blot of nuclear
extracts from Mecp2tm1.1Jae mutant () and wt mouse brain. CM, chicken erythrocyte histone marker. Top: SDS–PAGE loadings were normalized based
on histone H4 contents. Bottom: Western blots were performed using C-terminal MeCP2 (left) or N-terminal MeCP2 (right) antibodies. Both of them
label a higher MW band in wt nuclear extracts but only the C-terminal antibody labels a lower MW band in the mutant (), consistent with the
presence of a truncated MeCP2 protein with an N-terminal deletion in the MBD. (C) RT–PCR analysis of wtMeCP2 and MeCP2 expression in brain.
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Wild-type MeCP2 has been shown to be differentially
expressed in various brain regions, with the highest expres-
sion in cerebellum and cortex (48–50). Therefore, and
because of the reduced expression of the protein, we
decided to check its expression in different regions of the
brain. As seen in Figure 2, MeCP2 is expressed through-
out different sections of the brain. However, although a
noticeable increase in the expression of wtMeCP2 was
detected in wt cortex as previously described, no signifi-
cant difference could be observed for the expression of
MeCP2 among different regions of the Mecp2tm1.1Jae
mutant brain.
To assess whether the mutant protein is expressed in
peripheral tissues, we also measured MeCP2 levels in the
liver. MeCP2 is expressed in Mecp2tm1.1Jae mutant
mouse liver, but the amount of protein expressed is only
12±1% of that of wtMeCP2 expressed in wt mice (results
not shown). The reason for the further decrease of
MeCP2 in this tissue when compared with brain is not
clear, but it could be related to the faster turnover rate of
proteins in liver when compared with brain (51,52).
"MeCP2 exhibits an unusual cellular distribution
Previous immunohistochemical data from the
Mecp2tm1.1Jae line have been contradictory, with the
original study showing a loss of immunoreactivity
in histological sections of hippocampus and cerebellum
[see (29), Figure 1F], while a subsequent study found
diffuse MeCP2 staining in the hippocampus [see
(31), Figure 2G]. We re-investigated this issue by
double-immunolabelling cortical brain slices using the
mouse N-terminal a-MeCP2 and a chicken C-terminal
a-MeCP2 to compare wt males, mutant males and hetero-
zygous Mecp2+/ females (Figure 3A). We found that suc-
cessful double-immunolabelling was highly sensitive to
tissue fixation conditions, which may account for the dis-
crepant results in previous reports. The immunoreactivity
of the C-terminal antibody was robust under most fixation
conditions, but the N-terminal antibody immunoreactivity
was extremely sensitive to overfixation, and was only
reliably obtained after a brief formaldehyde fixation
using a pH-shift protocol (53). In wt males, both
antibodies labelled all neurons with a typical staining
pattern showing bright puncta against a diffuse nuclear
background (Figure 3A, top). Immunolabelled puncta
co-localized with heterochromatin regions, as previously
described (3,54). In hemizygous Mecp2/y mutant males,
only the C-terminal antibody was immunoreactive, and
nuclear labelling was faint and diffuse, with no puncta
observed (Figure 3A, bottom). To facilitate comparison
of the subcellular distribution patterns of wt with
mutant MeCP2 in vivo, heterozygous females were
obtained from a cross of the Mecp2tm1.1Jae line with the
B6.Cg-Tg(Thy1-YFPH)2Jrs/J line, which express YFP in
a subset of cortical neurons. Heterozygous Mecp2+/
females showed a mixture of the two patterns of
immunoreactivity observed in males. When imaged
under high-exposure conditions to amplify the fluores-
cence signal, wt MeCP2 labelled with both antibodies
was strictly localized to the nucleus. In neurons labelled
by the C-terminal antibody alone, immunoreactivity was
also observed in the cytoplasm, extending up into the
primary apical dendrite, albeit at much lower levels. The
marked difference in nuclear staining at the border of the
nucleus relative to adjacent cytoplasm indicated that
MeCP2 still retained a predominantly nuclear
localization.
To better characterize the cytoplasmic versus nuclear
localization of MeCP2, the cytoplasmic and nuclear frac-
tions of brain cells were obtained and analysed by western
blot (Figure 3B). The quantification was carried out using
anti-rabbit IRDye-conjugated fluorescent antibodies. In
mutant brain tissue, 27±3% of the MeCP2 is
detected in the cytoplasmic fraction as opposed to 3%
of MeCP2, in agreement with the imunohistochemical
data shown in Figure 3A. Interestingly, although the
NLS is retained, the presence of mutant MeCP2 in the
cytoplasm at low levels also suggests either a dysfunction
or reversibility of nuclear transport.
"MeCP2 exhibits even distribution throughout nuclei and
is associated with a significantly reduced nuclear size in
the neuronal nuclei of Mecp2tm1.1Jae mutant mice
To look in more detail at the nuclear distribution of
MeCP2 with respect to wt MeCP2 in live cells, particu-
larly in light of potential fixation artifacts, Neuro-2A cells
were transfected with GFP-MeCP2 and GFP-MeCP2
plasmid expression constructs. As seen in Figure 4A and B,
the wt GFP-MeCP2 exhibits enrichment in the pericentric
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Figure 2. Distribution of wtMeCP2 and MeCP2 in different sections
of the brain. The upper and lower part show a western blot analysis
using an MeCP2 and histone H3 antibody, respectively, of the SDS–
PAGE analysis of the nuclear protein composition shown in the
middle. CB: cerebellum; CT: cortex and MB: midbrain.
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pan-cellular distribution and seems to be homogeneous
throughout the nucleoplasm unlike either wt protein or
the distribution of DNA as revealed by Hoechst staining
(Figure 4A). This is similar to what was observed
immunohistochemically with the native MeCP2 in brain
tissue sections (Figure 3A). The absence of correlation
between DNA distribution (Hoechst staining) and GFP-
MeCP2 is illustrated quantitatively in the line-scan
(Figure 4B). Furthermore, the ratio of the variability of
GFP-MeCP2 staining relative to Hoechst staining is the
inverse of that observed in the wt (Figure 4C). Moreover, in
agreement with what was observed in cortical neurons in
Figure 3, a substantial component of GFP-MeCP2 is
distributed in the cytoplasm.
The nuclear distribution alteration that we observed for
GFP-MeCP2 is similar to initial observations by Nan
et al. (3) using mouse L cells. Similarly, Matsumura
et al. (55) found that in mouse NIH 3T3 cells transfected
with a truncated MeCP2 lacking the complete N-terminal
region (including the MBD), the mutant protein also
failed to efficiently retain in chromocenters. Moreover,
this construct exhibited a diffuse nuclear distribution
albeit with subtle enrichment in chromocenters (55). It is
important to mention here that in both instances, trans-
fections were carried out in the background of the native
wt MeCP2, and the increased presence at chromocenters
could arise from the binding of the wt form.
In the course of these experiments, we noticed that
transfection of Neuro-2A cells with GFP-MeCP2
systematically resulted in a decrease in the volume of the
nuclei when compared with the cells transfected with GFP-
MeCP2, similar to what has been observed in neurons of
the Mecp2tm1.1Jae mouse (29). A quantification of this phe-
nomenon carried out by comparison of the nuclear size in
wt and Mecp2tm1.1Jae mouse cortical neurons showed a
21% decrease in the latter (Figure 4D and E). Qualitative
observations of reduced neuronal nuclear size in the hippo-
campus were made in the original publication describing
Mecp2tm1.1Jae line, but these were not quantified (29).
Interestingly, the decreased nuclear size we observed is
comparable with the 28% reduction in neuronal nuclear
size in the brains of MeCP2-null Mecp2tm1.1Bird mice (56).
An MeCP2-related size dependence was also observed in
embryonic stem cells by the same authors, and it has
attributed to an increase in histone H1 on MeCP2 depletion
(24,56). Similarly, neurons from theMecp2tm1.1Bird line were
shown to have smaller chromocenters and an increase in
the number of nucleoli that exhibit a smaller size when
compared with the wt neurons (57). However, as we have
described earlier, the brain cells still retain a significant
amount (35%) of MeCP2 in Mecp2tm1.1Jae (Figure
1B–3B), while retaining the exact same amount of histone
H1 (Figure 4F). This suggests that the decrease in nuclear
volume and nucleolar organization on MeCP2 depletion is
not the direct result of a compensatory H1 increase but
rather of an MBD-dependent change in MeCP2-mediated
chromatin organization that is normally associated to an
increase in size of the nucleus.
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Figure 3. MeCP2 has altered nuclear distribution in fixed brain tissue and is present in the cytoplasm. (A) Confocal fluorescence images of MeCP2-
immunolabelled coronal sections of motor cortex layer 5. Top eight panels (males): Nuclei are counter-stained with YO-PRO-1 (blue). Neuronal nuclei
are larger, typically with bright punctate staining corresponding to dense heterochromatin, whereas glial nuclei are smaller and sometimes irregularly
shaped. In wt (Mecp2+/y) males, both a-N-terminal (green) and a-C-terminal (red) MeCP2 immunolabelling show bright puncta against a diffuse nuclear
background. In MeCP2J mutant (Mecp2-/y) males, a-N-terminal MeCP2 labelling is absent, whereas faint diffuse nuclear a-C-terminal MeCP2 labelling
is still observed, consistent with the N-terminal deletion and absence of the MBD. Glial MeCP2 signal is not evident in either genotype. Scale
bar=40mm. Bottom six (female): Heterozygous YFP+ Mecp2 +/ females have a mixture of both MeCP2 immunolabelling patterns (a-N-terminal,
blue; a-C-terminal, red). a-C-terminal-MeCP2 labelling is comparatively faint in mutant cells, but can be seen in a high-exposure image (bottom left,
greyscale). Under high exposure, immunolabelling in wt neurons for both antibodies is bright to oversaturated, but it remains exclusively nuclear
(arrow #3). In mutant neurons, faint diffuse a-C-terminal MeCP2 immunolabelling is predominantly nuclear, but it also occurs in the cytoplasm
extending into dendrites (arrows #1, #2). Scale bar=40mm. (B) SDS–PAGE (1) and western blot (2) analysis of overall MeCP2 present in wt and
mutant brain in comparison with the cytoplasmic (C) and nuclear (N) fractions. The red asterisk indicates a degradation product of wt MeCP2.
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"MeCP2 exhibits decreased nucleosome-binding affinity
Although all the results described so far indicate that
MeCP2 is able to localize to the nucleus, its binding
to chromatin remained to be established. To this end,
nuclei from wt and Mecp2tm1.1Jae mutant mice were
isolated, digested with micrococcal nuclease and
fractionated as described earlier (22). As shown in
Figure 5A despite the reduced amount of MeCP2
present in the Mecp2tm1.1Jae mouse and the lack of a
functional MBD, mutant MeCP2 exhibits a similar par-
titioning to the wt on nuclease digestion in both the wt
and mutant mice. The fractions exhibited a similar bio-
chemical composition (Figure 5B and C), although a
larger quantity of di-nucleosomes was consistently
observed in nuclei from Mecp2tm1.1Jae mouse brain as
compared with the wt (see Figure 5C SE-). Fraction
SI, which is highly enriched in Pol2 (58), contained the
largest amount of MeCP2 in both instances (Figure 5A).
On sucrose gradient fractionation (Figure 5D), both
MeCP2 and MeCP2 remained bound to mono-nucleo-
somes of the SI fraction and in both instances a similar
amount of free (non-nucleosome-bound) MeCP2 (sedi-
menting at the upper part of the gradient) is present in
this fraction as described previously (22). MeCP2 is also
bound to the mono-nucleosome and di-nucleosomes of
the SE fraction, although no free sedimenting fraction
was observed for MeCP2 (Figure 5E).
A time course of micrococcal nuclease digestion of
cell nuclei (Figure 6A) showed that chromatin
from Mecp2tm1.1Jae mutant brain tissue digested much
faster than chromatin from wt brains, but at a similar
rate as wt liver nuclei. Interestingly, a di-nucleosome–
‘resistant’ particle is observed at high-digestion times
(Figure 6A, SE, 24 and 32min), as it was also
observed in Figure 5C, SE. Although the differences in
the micrococcal nuclease digestion rates could be
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Figure 4. (A–C) MeCP2 distribution is altered in Neuro-2A cells and does not concentrate in heterochromatin. (A) Live Neuro-2A cells expressing
GFP-tagged wt or MeCP2 from transfected plasmid constructs. Nuclei were counterstained with Hoechst 33 342. wt GFP-MeCP2 is restricted to
the nucleus and co-localizes with heterochromatin puncta. Mutant GFP-MeCP2 is diffuse throughout the cell but reaches its highest concentration
in the nucleus. Dark patches in the nucleus co-localize with bright Hoechst puncta, indicating reduced levels in heterochromatin. Red arrows indicate
end points of the line segments plotted in (B). Scale bar=20 mm. (B) Line plots of greyscale intensities for GFP-MeCP2 (left axis) and Hoechst
33342 (right axis). Although GFP-MeCP2 peak intensities coincide with Hoechst staining and are brightest at heterochromatin puncta, this correl-
ation is not observed with GFP-MeCP2. Greyscale values were squared to highlight subtle differences in staining patterns. (C) The ratio of the
variability of GFP-MeCP2 staining relative to Hoechst staining is the inverse of that observed in the wt. The coefficient of variation was obtained
for both GFP and Hoechst greyscale intensity over the entire nucleus. In the wt, a ratio value >1 is observed, indicating a greater variance in the
distribution of GFP-MeCP2 relative to Hoechst staining. The inverse is observed in the mutant (Mann–Whitney U-test, P< 0.0001). (D and E)
Nuclear size is reduced in cortical neurons of MeCP2 mutant mice. (D) Wide field fluorescence images of Hoechst 33342-stained nuclei. Mutant
brain tissue contains a greater proportion of small nuclei. Scale bar=10 mm. (E) The average nuclear area is reduced by 20.2% in 6-week-old mutant
males (85.00±1.04 mm2 in wt versus 67.84±1.71mm2 in mutant, t4=9.284, P< 0.01). (F) Western blot analysis of histone H1 and histone H3 with
an IRDye fluorescent antibody detection. CE: chicken erythrocyte histones used as a histone marker. Bwt: nuclear brain from wt mice; B: nuclear
brain from Mecp2tm1.1Jae mutant; Lwt: nuclear liver from wt mice; L: nuclear liver from Mecp2
tm1.1Jae mutant. The numbers underneath the image
represent the percentile of MeCP2 with respect to brain wt taken as 100% (in red) and of H1 with respect to liver wt taken as 100% (in black).
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present in the different cell types (being the lowest in the
wt liver), the amount of histone H1 was almost identical
in all of them (Figure 4F). It is possible that the slower
rate of digestion observed in wt brain cell nuclei is the
result of a higher MeCP2 content in these cells, which is
associated with a preference for binding the linker
regions connecting adjacent nucleosomes (17,20). The
preference of wt MeCP2 for linker DNA in proximity
to the nucleosome, similar to histone H1, is likely the
result of the highest levels of DNA methylation within
these chromatin regions (59) and the affinity of MeCP2
for four-way junction DNA (60), a structure that resem-
bles the DNA organization at its site of entry and exit
from the nucleosome. Accordingly, histone H1, which
also binds at this nucleosome site, exhibits a similar pref-
erence for four-way junctions (61).
Interestingly, the presence of a structurally and func-
tionally impaired MBD in MeCP2 results in a highly
transient weak chromatin binding as indicated by the
FRAP experiments (Figure 6B). As shown, at almost
any time, most of GFP-MeCP2 is free in solution, and
the half time residence (t50) of the protein was not meas-
urable (below detection limits). GFP-MeCP2 had a t50
of 1.3 s in comparison with 21 s for the wt GFP-MeCP2
(Figure 6B, blue diamonds), in agreement with similar
results that used GFP-MeCP2 constructs lacking the
whole MBD (62) [compare Figure 6A of Kumar et al.
(62) with Figure 6B]. Thus, although we have shown
that MeCP2 is able to bind to chromatin in the cells of
the Mecp2tm1.1Jae mouse model, the binding is weak and
dynamic. This finding suggests that in vivo the contribu-
tion of the MBD of MeCP2 is critical for proper chroma-
tin binding, and it largely overrides its electrostatic
interaction potential. The in vivo relevance of the FRAP
data is validated by the similar nuclear/cytoplasmic local-
ization (Figure 4A and B) and decreased nuclear size
(Figure 4A) of cells transfected with similar expression
vectors of GFP-tagged MeCP2 when compared with
neurons from the Mecp2tm1.1Jae mouse (Figure 3A
and 4D). Moreover, a single-point mutation in the
region of MBD truncated in the Mecp2tm1.1Jae mouse
model exhibits a FRAP that is almost identical to
MeCP2 lacking MBD (62) or to shown in Figure 6B.
DISCUSSION
Although the interactions of MeCP2 with different chro-
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Figure 5. Brain chromatin distribution of wtMeCP2 and MeCP2 in wt and Mecp2tm1.1Jae mutant mice (). (A) Western blots of nuclear MeCP2
partitioning in the SI, SE and P chromatin fractions on digestion with micrococcal nuclease (20). (B) SDS–PAGE analysis of the SI and SE
chromatin fractions. Note the absence of histone H1 (square) in SI. (C) Native PAGE analysis of the DNA composition of the SI and SE chromatin
fractions. Cf: pBR322-CfoI–digested DNA marker (the numbers on the left hand side of the gel correspond to the size of the electrophoretic bands in
base pairs); D: di-nucleosomes; M: mono-nucleosomes. The arrow head points to the increased presence of di-nucleosomes in Mecp2tm1.1Jae mutant
mice. (D) Sucrose gradient fractionation of the SI chromatin fraction. The graph (upper panel) depicts the absorbance (260 nm) profile of the
numbered fractions collected along the gradient, shown in the lower panel by western blot analysis using MeCP2 antibody. (E) Sucrose gradient
fractionation of the SE chromatin fraction [as described in (D)].
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in vitro (2), its binding to chromatin in the native in vivo
setting is less well understood. Wild-type MeCP2 E1 has a
pI of 9.9, and removal of the protein sequence encoded by
exon 3 [which removes part of the MBD and part of the
N-terminal region (Figure 1A)] renders a protein
(MeCP2) with a 10.1 pI, which is close to that of
histone H1 (i.e. human H1.2, pI=10.9). Hence, the inter-
action of MeCP2 in vitro with the nucleosome or nucleo-
some array substrate in the absence of competitor DNA
can be largely electrostatically driven (20). The extent to
which this mimics physiological conditions and the preva-
lence of the ionic interactions over those of the MBD
domain within the cell is not well known. The in vitro
studies of MeCP2 and reconstituted nucleosome
complexes have provided evidence for the existence of
several specific sites of interaction of MeCP2 with the nu-
cleosome (18,63) in addition to its MBD. Little is known
about the role these sites play in the interaction of MeCP2
with the native chromatin template in vivo.
To address some of these issues in the in vivo setting, we
have taken advantage of the Mecp2tm1.1Jae RTT mouse
model, as shown in Figure 1 and 2, which expresses
MeCP2 in all tissues examined, albeit at a lower
amount than MeCP2 in wt mice (50% between cyto-
plasm and nuclei). The data obtained with this model
nicely complement previous experiments directed to
understand the role of the MBD in MeCP2–chromatin
binding in vitro, based on transfection of plasmids
encoding wt and truncated MeCP2 constructs (3,55,62).
The cause of reduced levels of MeCP2 [Figure 1 B and
(29)] in the Mecp2tm1.1Jae mouse model is not obvious,
however. Although the data shown in Figure 1C could
suggest a decrease inMecp2 expression or mRNA instabil-
ity, the statistical significance for the observed difference is
not strong. A lower level of expression would be in agree-
ment with the lower presence of MeCP2 RNA detected
by northern blot analysis (29). However, the high variabil-
ity of the data (Figure 1C) could also be in agreement with
a previous study that found no difference in mRNA abun-
dance using the same technique in another characteriza-
tion of the same mouse model (30). A potential alternative
and/or complementary explanation could be a higher
cellular turnover of MeCP2 that binds transiently to
the chromatin template (Figure 6B) and partitions itself
between the cytoplasmic and nuclear compartments differ-
ently than native MeCP2 in wt mouse (Figure 3) and in
transfected cells (Figure 4). In this regard, it is interesting
to note that removal of exon 3 in MeCP2 results in the
loss of one of the PEST sequences (4) of the protein but
does not affect the NLS (Figure 1A). PEST sequences are
hydrophilic, at least 12 amino acids in length, and typic-
ally signal the protein containing them for rapid proteo-
lytic degradation by the 26S ubiquitin proteasome system
after ubiquitination at lysine residues within the PEST
sequence (64,65). Notably, phosphorylation within PEST
motifs precedes ubiquitination of proteins (66); one of the
best characterized sites of MeCP2 phosphorylation (S80 in
MeCP2 E2; S97 in MeCP2 E1) (67), as well as one of the
recently identified ubiquitination sites (K82/K99) (58),
both fall within one of these regions. Therefore, it is rea-
sonable to assume that the decrease in expression and the
unusual cytoplasmic/nuclear partitioning ratio are just a
reflection of an enhanced or altered protein turnover.
We observed a more diffuse distribution of MeCP2
throughout the nucleus of the Mecp2tm1.1Jae mouse
model (Figure 3 and 4), which coincides with a reduction
in the nuclear size, both in the comparison of transfected






















































Figure 6. Nuclear size, histone H1 composition and chromatin accessibility of wt and Mecp2tm1.1Jae mutant mice (). (A) Agarose gel electrophoresis
of the DNA fragments obtained by micrococcal nuclease time course digestions of mouse brain and liver at the times indicated on top of the gel. M1
and M2 are the GeneRuler 50 bp and GeneRuler 1 kb DNA ladder markers (Fermentas), respectively. The arrow points to the higher intensity of the
band corresponding to the di-nucleosome in the SE fraction of the Mecp2tm1.1Jae mutant mice nuclei at high times of nuclease digestion. Bwt, B and
Lwt same as in Figure 4F. D: di-nucleosome; M: mono-nucleosome; T: tri-nucleosome. The numbers under the lanes shown in SE indicate the ratios
D: M as determined by densitometry. (B) FRAP of wtMeCP2-GFP and MeCP2-GFP.
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histone H1 content (Figure 4F). Such heterogeneous dis-
tribution of MeCP2, when compared with the wt, is in
good agreement with the results of Nan et al. (3), who
used an MTaseS cell line that contains only 5% of the
levels of methyl cytosine to show that the location of
MeCP2 depends on DNA methylation.
It is possible also that the lower levels of MeCP2 ex-
hibited by the Mecp2tm1.1Jae mouse model are indirectly
contributing to this model’s phenotype as opposed to
MeCP2 itself. In other words, a decrease in the nuclear
volume could result in a concentration increase of all the
nuclear proteins relative to wt, which could lead to all
kinds of biological effects currently unpredictable from
our data.
Histone H1 and MeCP2 have both been shown to bind
cooperatively to DNA and to methylated DNA, respect-
ively (18,68). The binding constant of MeCP2 to
methylated DNA is 40 109M (18,69). This is much
lower than that corresponding to the binding of the SPKK
motif characteristic of the C-terminal motif of some H1
histones (4 109M) (70), or that determined for the
binding of H1 to four-way junction DNA constructs
(16 109M) (71). The binding affinity of MeCP2 for
methylated DNA is also lower than that of histone H1
to the nucleosome (10 109M) (72). Consequently, the
mechanisms involved in the competition of MeCP2 with
histone H1 for binding to the methylated region of the
genome are ambiguous (21). Interestingly, the amount of
histone H1 remains the same in the brains ofMecp2tm1.1Jae
mice (Figure 4F), suggesting that the reduced levels of
MeCP2 relative to wt do not result in a compensatory
increase by histone H1, as compared with previous data
from embryonic stem cells lacking MeCP2 (56).
Furthermore, an increase in H1 should have resulted in
a more compact chromatin organization that was more
resilient to nuclease accessibility, in contrast to what we
observe (Figure 6A). Moreover, this also indicates that the
unusually large nuclear volume size of wt neurons where
MeCP2 is present in large amounts (Figure 4D) is not the
result of a histone H1 deficiency but of the inherent
presence of native MeCP2.
Ultimately, any interpretation of the interactions of
MeCP2 with chromatin needs to take into consideration
the difference in the binding affinity of MBD proteins,
including MeCP2, for specific methylated DNA
compared with generic non-methylated DNA binding.
The difference exhibits a decrease from the nanomolar
to the micromolar range (73) (10-fold for MeCP2),
which is likely exacerbated by the presence of chromatin
and is far beyond the binding affinity of linker histones.
Therefore, in addition to the lacking the ability to bind to
methylated DNA, any binding of MeCP2 to chromatin
will be secondary to H1 binding and will have to rely on
other chromatin-binding sites of the molecule.
The in vitro characterization of the interaction of
MeCP2 with nucleosomal templates has shown that, in
addition to the MBD, MeCP2 contains a methylation-in-
dependent chromatin-binding site at its C-terminal end
[residues 196–355 (312–501 in wt)]. The weakest inter-
action of MeCP2 in the absence of a functional MBD
observed by us (Figure 6B) and others (62) indicates
that within the cell, MeCP2 binds primarily to methylated
DNA through its MBD, and it is in turn further stabilized
by the interaction of its C-terminal end with the non-
methylated DNA. This occurs in the opposite order to
an earlier proposal based on their in vitro analysis (18).
The presence of binary chromatin-binding sites within the
same terminal region of MeCP2, such as the 195–271
(311–387 in wt) and 272–354 (388–470 in wt) (18) or
the 63–102 (179–218 in wt), DNA-binding domain of the
intervening domain (ID) (63) may be responsible for the
‘resistant’ nucleosome dimers observed on nuclease diges-
tion of brain chromatin (Figure 5E and 6A). Such struc-
tures may correspond to the existence of MeCP2
molecules sandwiched between two adjacent nucleosomes
through interactions with these regions (63).
The MBD of MeCP2 thus seems to confer high specificity
and affinity to chromatin binding within the cell. It is im-
portant to point out here that the removal of exon 3 of
MeCP2 in theMecp2tm1.1Jae model in addition to an import-
ant part of MBD also removes 114 amino acids adjacent to
this domain in the N-terminal region (Figure 1A). It has
been shown that this region structurally synergises with the
MBD to increase its binding to DNA and to chromatin (63).
The coupling between these two regions most likely allows
for both recognition of the four-way junction-like DNA or-
ganization at the entry and exit site of the DNA in the nu-
cleosome, as well as for DNA methylation sites, which
preferentially occur in linker regions of chromatin (59). It
is possible that in cell types such as neurons where MeCP2 is
highly abundant (20,22) other methylation-independent
chromatin interactions such as those observed here for
MeCP2 also take place. These are likely to involve the
C-terminal end of MeCP2, and their more labile interaction
with chromatin could account for the apparently unbound
MeCP2 that appears on the SI and SE fractions that are
quickly released on micrococcal nuclease digestion of wt
brain nuclei (4). Overall, the results presented here clearly
demonstrate that in the in vivo setting, the DNA methyla-
tion-independent interactions of MeCP2 with chromatin are
transient, weak and secondary in nature.
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(2001) Characterization of the stability and folding of H2A.Z
chromatin particles: implications for transcriptional activation.
J. Biol. Chem., 276, 41945–41949.
39. Yager,T.D. and van Holde,K.E. (1984) Dynamics and equilibria
of nucleosomes at elevated ionic strength. J. Biol. Chem., 259,
4212–4222.
40. Abbott,D.W., Chadwick,B.P., Thambirajah,A.A. and Ausio,J.
(2005) Beyond the Xi: macroH2A chromatin distribution and
post-translational modification in an avian system. J. Biol. Chem.,
280, 16437–16445.
41. Thambirajah,A.A., Dryhurst,D., Ishibashi,T., Li,A., Maffey,A.H.
and Ausio,J. (2006) H2A.Z stabilizes chromatin in a way that is
dependent on core histone acetylation. J. Biol. Chem., 281,
20036–20044.
42. Dryhurst,D., Ishibashi,T., Rose,K.L., Eirin-Lopez,J.M.,
McDonald,D., Silva-Moreno,B., Veldhoen,N., Helbing,C.C.,
Hendzel,M.J., Shabanowitz,J. et al. (2009) Characterization of the
Nucleic Acids Research, 2013, Vol. 41, No. 9 4899
Downloaded from https://academic.oup.com/nar/article-abstract/41/9/4888/2409621
by guest
on 24 July 2018
histone H2A.Z-1 and H2A.Z-2 isoforms in vertebrates. BMC
Biol., 7, 86.
43. Carrero,G., McDonald,D., Crawford,E., de_Vries,G. and
Hendzel,M.J. (2003) Using FRAP and mathematical modeling to
determine the in vivo kinetics of nuclear proteins. Methods, 29,
14–28.
44. Kwon,M.J., Oh,E., Lee,S., Roh,M.R., Kim,S.E., Lee,Y.,
Choi,Y.L., In,Y.H., Park,T., Koh,S.S. et al. (2009) Identification
of novel reference genes using multiplatform expression data and
their validation for quantitative gene expression analysis. PloS
One, 4, e6162.
45. Livak,K.J. and Schmittgen,T.D. (2001) Analysis of relative gene
expression data using real-time quantitative PCR and the 2[-Delta
Delta C(T)] Method. Methods, 25, 402–408.
46. Walzak,A.A., Veldhoen,N., Feng,X., Riabowol,K. and
Helbing,C.C. (2008) Expression profiles of mRNA transcript
variants encoding the human inhibitor of growth tumor
suppressor gene family in normal and neoplastic tissues. Exp. Cell
Res., 314, 273–285.
47. Wong,M.L. and Medrano,J.F. (2005) Real-time PCR for mRNA
quantitation. Biotechniques, 39, 75–85.
48. Shahbazian,M.D., Antalffy,B., Armstrong,D.L. and Zoghbi,H.Y.
(2002) Insight into Rett syndrome: MeCP2 levels display tissue-
and cell-specific differences and correlate with neuronal
maturation. Hum. Mol. Genet., 11, 115–124.
49. Jung,B.P., Jugloff,D.G., Zhang,G., Logan,R., Brown,S. and
Eubanks,J.H. (2003) The expression of methyl CpG binding
factor MeCP2 correlates with cellular differentiation in the
developing rat brain and in cultured cells. J. Neurobiol., 55,
86–96.
50. Zachariah,R.M., Olson,C.O., Ezeonwuka,C. and Rastegar,M.
(2012) Novel MeCP2 isoform-specific antibody reveals the
endogenous MeCP2E1 expression in murine brain, primary
neurons and astrocytes. PLoS One, 7, e49763.
51. Lajtha,A., Latzkovits,L. and Toth,J. (1976) Comparison of
turnover rates of proteins of the brain, liver and kidney in mouse
in vivo following long term labeling. Biochim. Biophys. Acta, 425,
511–520.
52. Johnson,H.A., Baldwin,R.L., Klasing,K.C., France,J. and
Calvert,C.C. (2000) A rodent model of protein turnover used to
design an experiment for measuring the rates of channeling,
recycling and protein synthesis. J. Nutr., 130, 3097–3102.
53. Berod,A., Hartman,B.K. and Pujol,J.F. (1981) Importance of
fixation in immunohistochemistry: use of formaldehyde solutions
at variable pH for the localization of tyrosine hydroxylase.
J. Histochem. Cytochem., 29, 844–850.
54. Kishi,N. and Macklis,J.D. (2004) MECP2 is progressively
expressed in post-migratory neurons and is involved in neuronal
maturation rather than cell fate decisions. Mol. Cell. Neurosci.,
27, 306–321.
55. Matsumura,S., Persson,L.M., Wong,L. and Wilson,A.C. (2010)
The latency-associated nuclear antigen interacts with MeCP2 and
nucleosomes through separate domains. J. Virol., 84, 2318–2330.
56. Yazdani,M., Deogracias,R., Guy,J., Poot,R.A., Bird,A. and
Barde,Y.A. (2012) Disease modeling using embryonic stem cells:
MeCP2 regulates nuclear size and rna synthesis in neurons. Stem
Cells, 30, 2128–2139.
57. Singleton,M.K., Gonzales,M.L., Leung,K.N., Yasui,D.H.,
Schroeder,D.I., Dunaway,K. and LaSalle,J.M. (2011) MeCP2 is
required for global heterochromatic and nucleolar changes during
activity-dependent neuronal maturation. Neurobiol. Dis., 43,
190–200.
58. Gonzales,M.L., Adams,S., Dunaway,K.W. and LaSalle,J.M.
(2012) Phosphorylation of distinct sites in MeCP2 modifies
cofactor associations and the dynamics of transcriptional
regulation. Mol. Cell. Biol., 32, 2894–2903.
59. Felle,M., Hoffmeister,H., Rothammer,J., Fuchs,A., Exler,J.H. and
Langst,G. (2011) Nucleosomes protect DNA from DNA
methylation in vivo and in vitro. Nucleic Acids Res., 30,
2128–2139.
60. Galvao,T.C. and Thomas,J.O. (2005) Structure-specific binding of
MeCP2 to four-way junction DNA through its methyl CpG-
binding domain. Nucleic Acids Res., 33, 6603–6609.
61. Varga-Weisz,P., van Holde,K. and Zlatanova,J. (1993)
Preferential binding of histone H1 to four-way helical junction
DNA. J. Biol. Chem., 268, 20699–20700.
62. Kumar,A., Kamboj,S., Malone,B.M., Kudo,S., Twiss,J.L.,
Czymmek,K.J., LaSalle,J.M. and Schanen,N.C. (2008) Analysis of
protein domains and Rett syndrome mutations indicate that
multiple regions influence chromatin-binding dynamics of the
chromatin-associated protein MECP2 in vivo. J. Cell Sci., 121,
1128–1137.
63. Ghosh,R.P., Nikitina,T., Horowitz-Scherer,R.A., Gierasch,L.M.,
Uversky,V.N., Hite,K., Hansen,J.C. and Woodcock,C.L. (2010)
Unique physical properties and interactions of the domains of
methylated DNA binding protein 2. Biochemistry, 49, 4395–4410.
64. Rechsteiner,M. and Rogers,S.W. (1996) PEST sequences and
regulation by proteolysis. Trends Biochem. Sci., 21, 267–271.
65. Rogers,S., Wells,R. and Rechsteiner,M. (1986) Amino acid
sequences common to rapidly degraded proteins: the PEST
hypothesis. Science, 234, 364–368.
66. Spencer,M.L., Theodosiou,M. and Noonan,D.J. (2004) NPDC-1,
a novel regulator of neuronal proliferation, is degraded by the
ubiquitin/proteasome system through a PEST degradation motif.
J. Biol. Chem., 279, 37069–37078.
67. Tao,J., Hu,K., Chang,Q., Wu,H., Sherman,N.E., Martinowich,K.,
Klose,R.J., Schanen,C., Jaenisch,R., Wang,W. et al. (2009)
Phosphorylation of MeCP2 at Serine 80 regulates its chromatin
association and neurological function. Proc. Natl Acad. Sci. USA,
106, 4882–4887.
68. Watanabe,F. (1986) Cooperative interaction of histone H1 with
DNA. Nucleic Acids Res., 14, 3573–3585.
69. Ballestar,E., Yusufzai,T.M. and Wolffe,A.P. (2000) Effects of Rett
syndrome mutations of the methyl-CpG binding domain of the
transcriptional repressor MeCP2 on selectivity for association
with methylated DNA. Biochemistry, 39, 7100–7106.
70. Suzuki,M. (1989) SPKK, a new nucleic acid-binding unit of
protein found in histone. EMBO J., 8, 797–804.
71. Hill,D.A. and Reeves,R. (1997) Competition between HMG-I(Y),
HMG-1 and histone H1 on four-way junction DNA. Nucleic
Acids Res., 25, 3523–3531.
72. Caterino,T.L., Fang,H. and Hayes,J.J. (2011) Nucleosome linker
DNA contacts and induces specific folding of the intrinsically
disordered H1 carboxyl-terminal domain. Mol. Cell. Biol., 31,
2341–2348.
73. Fraga,M.F., Ballestar,E., Montoya,G., Taysavang,P., Wade,P.A.
and Esteller,M. (2003) The affinity of different MBD proteins for
a specific methylated locus depends on their intrinsic binding
properties. Nucleic Acids Res., 31, 1765–1774.
4900 Nucleic Acids Research, 2013, Vol. 41, No. 9
Downloaded from https://academic.oup.com/nar/article-abstract/41/9/4888/2409621
by guest
on 24 July 2018
